LOGIN  |  REGISTER
Astria Therapeutics
Chimerix

Sonida Senior Living Announces Second Quarter 2025 Earnings Release Date and Conference Call

July 29, 2025 | Last Trade: US$25.27 0.30 -1.17

DALLAS / Jul 29, 2025 / Business Wire / Sonida Senior Living, Inc. (“Sonida” or the “Company”) (NYSE: SNDA), a leading owner, operator and investor in communities and services for seniors, today announced that it will issue its second quarter 2025 earnings results before the market opens for trading on Monday, August 11, 2025. The Company will then host a conference call and webcast to review its financial performance and operating results at 11:00 a.m. Eastern Time.

The dial-in number for the conference call is (800) 715-9871 (or +1 (646) 307-1963 for international callers), and the participant passcode is 4619110. A live webcast can be accessed here. All participants are asked to register and connect 10 minutes prior to the start of the call/webcast to ensure connectivity.

A webcast replay will be available on the Sonida IR website and accessible for replay for 12 months. A telephonic replay will be available for 7 days at (800) 770-2030, passcode 4619110.

About Sonida

Dallas-based Sonida Senior Living, Inc. is a leading owner, operator and investor in independent living, assisted living and memory care communities and services for senior adults. The Company provides compassionate, resident-centric services and care as well as engaging programming operating 96 senior housing communities in 20 states with an aggregate capacity of approximately 10,150 residents, including 83 communities which the Company owns (including four owned through joint venture investments in consolidated entities, four owned through a joint venture investment in an unconsolidated entity, and one unoccupied), and 13 communities that the Company manages on behalf of a third-party.

For more information, visit www.sonidaseniorliving.com or connect with the Company on Facebook, X or LinkedIn. 

Recursion

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page